CN1052419C - Herb medicine for treating diabetes mellitus - Google Patents

Herb medicine for treating diabetes mellitus Download PDF

Info

Publication number
CN1052419C
CN1052419C CN96109771A CN96109771A CN1052419C CN 1052419 C CN1052419 C CN 1052419C CN 96109771 A CN96109771 A CN 96109771A CN 96109771 A CN96109771 A CN 96109771A CN 1052419 C CN1052419 C CN 1052419C
Authority
CN
China
Prior art keywords
shares
treatment
diabetes
blood
herb medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96109771A
Other languages
Chinese (zh)
Other versions
CN1175424A (en
Inventor
裘晓富
李福奎
韩文生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN96109771A priority Critical patent/CN1052419C/en
Publication of CN1175424A publication Critical patent/CN1175424A/en
Application granted granted Critical
Publication of CN1052419C publication Critical patent/CN1052419C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

The present invention relates to a traditional Chinese herbal medicine used for diabetes treatment, which is prepared from the following components by weight proportion: 20 to 40 shares of coptis chinensis, 18 to 35 shares of flos lonicerae, 15 to 30 shares of astragalus hoangtchy, 15 to 30 shares of forsythia suspensa vahl and 3 to 10 shares of Chinese yam. The traditional Chinese herbal medicine is mainly used for auxiliary treatment on I type diabetes and II type diabetes of middle-aged and old-aged people, has the functions of yin nourishing, lung benefiting, blood glucose, blood fat and blood viscosity reduction, pancreatic island function strengthening and microcirculation improvement, and has the characteristics of unique raw material formula, conspicuous curative effect, low cost and no toxic or side effect.

Description

A kind of Chinese herb medicine for the treatment of diabetes
The present invention relates to treat the medicine of diabetes, specifically is to be the medicament of feedstock production with the Chinese herbal medicine.
Diabetes are one of several big diseases of serious harm human health in the world, and present therapeutic agent is all undesirable.For example, sulfaurea drugs and biguanide drug, curative effect is low, and side effect is big, for a long time with producing hyperlactacidemia, the caused mortality that has hypoglycemia; Sulfaurea drugs is for a long time with infringement liver, kidney and hemocyte.Insulin with producing antibody, increases dosage for a long time, easily impels microvascular disease.Though the Chinese patent medicine of treatment diabetes is also arranged at present, and effect is all not fairly obvious.
The purpose of this invention is to provide a kind of have blood sugar lowering, glucose in urine, blood fat, blood viscosity, the sharp lung of nourishing kidney, QI invigorating tonifying YIN, diabetes Chinese herbal treatment agent without any side effects.
Solution of the present invention is according to motherland's medical science dialectical the executing of diabetes treatment to be administered opinion, in conjunction with what make on Chinese medicine modern pharmacology and the clinic study basis, carry out acute and chronic toxicological test and pharmacodynamic study through national authority unit, by preferred Chinese medicine, clinic trial develops for many years, has the effect of nourishing kidney tonifying the lung, QI invigorating tonifying YIN, blood sugar lowering, blood fat, blood viscosity, enhancing islet function, microcirculation improvement.
The preparation that medicine of the present invention is made up of the following weight proportion raw material:
Rhizoma Coptidis 20-40 part, Flos Lonicerae 18-35 part, Radix Astragali 15-30 part, 1530 parts of Fructus Forsythiaes, Rhizoma Dioscoreae 3-10 part.
The formula optimization weight proportion scope of preparation medicine of the present invention is:
Rhizoma Coptidis 30-40 part, Flos Lonicerae 18-35 part, Radix Astragali 20-30 part, Fructus Forsythiae 20-30 part, Rhizoma Dioscoreae 5-10 part.
Above-mentioned pharmaceutical preparation can be said dosage form on any pharmaceutics, as powder, close ball, oral liquid, capsule etc.Incapsulate after preferably making powder, take very convenient.Capsule method of administration: every day 3 times, each 2-3 grain.
By 6 years nearly ten thousand patients' the clinical observation and the checking of several families hospital expert, the treatment diabetes curative effect is remarkable, has effects such as blood sugar lowering, blood fat reducing, reducing blood viscosity, microcirculation improvement.Clinical observation to: the effect that recovers non-obese diabetic insulin human secretory function is also arranged, but prophylactic treatment diabetic complication also, and can be as the adjuvant therapy medicaments of type i diabetes.
For showing the present invention to the treatment of diabetes effect, carried out the clinical observation of 347 examples, curative effect is better than matched group.All case all meets the diabetes diagnosis standard of The World Health Organization's proposition in 1980.Among the 347 routine patients, male 168 examples, women 179 examples: 12 years old-89 years old age (50.8 ± 10.0); The course of disease 1 month-29 years (7.7 ± 5 years): non-insulin-depending type (NNDDM) 300 examples, insulin-dependent (IDDM) 47 examples.Matched group 67 examples: male 29 examples, women 38 examples, 34 years old-82 years old age, (51.4 ± 10.5); The course of disease 3 months-22 years (7.1 ± 3.9 years).
All case is divided into 3 groups by the preceding treatment situation difference of going to a doctor: (1) is just sent out flat (being capsule preparations of the present invention, the as follows) treatment of blood glucose and is organized 152 examples, for the people that just falls ill did not accept any hypoglycemic drug, takes blood glucose merely and brings treatment under control; (2) it is bad and use blood glucose instead and bring treatment under control that self-controlled group 148 examples, past attempts are taken the other medicines therapeutic effect; (3) insulinize group 47 people, the patient of insulinize do not reach desirable control criterion and add blood glucose and bring treatment under control.
Therapeutic outcome: (seeing Table 1,2)
Blood glucose is respectively organized in table 1 treatment front and back, (x ± S) 2 hours after the meal blood glucose (mmol/L) of group n fasting glucose (mmol/L) glucose in urine restrains/24 hours in the glucose in urine variation
Treat rear flat treatment group 152 people 15.27 of onset blood sugar of the front treatment of the rear treatment of front treatment ± 5.87 8.24 ± 3.42 20.1 ± 8.19 9.87 ± 3.51 108.12 ± 36.61 19.86 ± 7 self-controlled group, 148 people 11.87 ± 4.20 9.23 ± 2.13 11.30 ± 2.48 9.98 ± 3.82 89.87 ± 32.62 23.48 ± 18 pancreas islet rope treatment groups, 47 people 11.76 ± 2.19 8.98 ± 3.12 18.87 ± 7.81 9.52 ± 3.89 78.76 ± 21.68 26.92 ± 22 control groups, 67 people 14.16 ± 4.12 9.87 ± 3.52 19.86 ± 9.24 10.52 ± 3.87 103.97 ± 58.71 21.10+16 after treating front treatment
Respectively organize as a result flat treatment group 152 people of group n produce effects enabledisable obvious effective rate % total effective rate % onset blood sugar 129 21 2 85 98.60 self-controlled group 148 people 118 23 7 79 95.00 insulinize groups 47 people 43 31 93 97.80 control groups 67 people 46 15 6 68 76.00 of efficacy determination before and after table 2 treatment
The patient who treats preceding 257 routine hyperlipidemia hypercholesterolemias is not obeying under the situation of other lipid lowerers.Obvious decline is all arranged, see Table 3.
The variation of blood fat before and after table 3 treatment
Mmol/L treatment back mmol/L before the 257 routine hyperlipidemia treatments
Triglyceride 2.45 ± 0.48 1.42 ± 0.49
Cholesterol 8.28 ± 0.52 4.82 ± 0.87
Be close on ten thousand routine patients clinicals through 6 and observe, the flat capsule of blood glucose has good hypoglycemic effect, and can prevent and treat diabetic complication.And have blood fat reducing, fall blood viscosity, comprehensive function such as microcirculation improvement.Blood glucose was brought the treatment group under control 21-50 days, and obvious effective rate reaches 85%, and total effective rate reaches 98.6%, and is high by 29% than matched group.Characteristics such as blood glucose is flat, and to have clinical side effects few, and the medicine source is abundant, and low price is evident in efficacy, and administrated method is easy are the reliable medicines of treatment type ii diabetes curative effect.It also is the ideal ancillary drug of type i diabetes.Has wide clinical generalization value.
Be a model case below:
Zhao takes advantage of newly, woman 62 years old, new base, Xinji City, Hebei province people from group, suffer from diabetes 9 years, once obeyed a large amount of multiple blood sugar lowering, also once arrived the stone city, the capital, Tianjin large hospital is gone to a doctor, the state of an illness is unstable always, blood glucose is higher, glucose in urine, general weakness, patient once lost confidence, it is better to listen others to take the flat curative effect of blood glucose afterwards, just has a gleam of hope in arms and makes a special trip to a certain place deep blue to seek medical advice, through my the training doctor of institute diagnosis and treatment, take our flat capsule for treating of achievement in research blood glucose, the 3 all blood glucose of taking medicine, it is normal that glucose in urine recovers substantially, begin to reduce dose, patient takes a turn for the better gradually, 1 first quarter moon of taking medicine, body weight is increased to 50 kilograms from 45 kilograms, whole body is strong, and is energetic, can do housework also can participate in light physical labor.Continue to take medicine and gradually reduce drug dose, took medicine 5 months, patient's dose reduces to minimum dose, obey 2 every day, blood glucose, glucose in urine are normal always, and board and lodging is normal, can participate in normal work, by repeatedly doing carbohydrate tolerance, blood glucose, glucose in urine, insulin test, each value all is normal, and patient body weight is 60 kilograms at present, only uses diet control, stopping will be 1 year half, and life, work are as the normal person.Zhao takes advantage of and newly meets the people just to say to be the flat diabetes of thoroughly having cured her of blood glucose.

Claims (4)

1, a kind of Chinese herb medicine for the treatment of diabetes is characterized in that it is the medicament of being made by the following weight proportion raw material:
Rhizoma Coptidis 20-40 part, Flos Lonicerae 18-35 part, Radix Astragali 15-30 part, Fructus Forsythiae 15-30 part, Rhizoma Dioscoreae 3-10 part.
2, the Chinese herb medicine of treatment diabetes according to claim 1 is characterized in that wherein the weight proportion of each raw material is:
Rhizoma Coptidis 30-40 part, Flos Lonicerae 18-35 part, Radix Astragali 20-30 part, Fructus Forsythiae 20-30 part, Rhizoma Dioscoreae 5-10 part.
3, the Chinese herb medicine of treatment diabetes according to claim 1 and 2 is characterized in that said preparation is a said dosage form on any pharmaceutics.
4, the Chinese herb medicine of treatment diabetes according to claim 3 is characterized in that said medicament is a Chinese medicinal capsule.
CN96109771A 1996-09-05 1996-09-05 Herb medicine for treating diabetes mellitus Expired - Fee Related CN1052419C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN96109771A CN1052419C (en) 1996-09-05 1996-09-05 Herb medicine for treating diabetes mellitus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN96109771A CN1052419C (en) 1996-09-05 1996-09-05 Herb medicine for treating diabetes mellitus

Publications (2)

Publication Number Publication Date
CN1175424A CN1175424A (en) 1998-03-11
CN1052419C true CN1052419C (en) 2000-05-17

Family

ID=5120597

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96109771A Expired - Fee Related CN1052419C (en) 1996-09-05 1996-09-05 Herb medicine for treating diabetes mellitus

Country Status (1)

Country Link
CN (1) CN1052419C (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1294936C (en) * 2004-03-12 2007-01-17 天津中新药业集团股份有限公司隆顺榕制药厂 Medicine for treating diabetes and its preparation method
CN103550485A (en) * 2013-10-14 2014-02-05 崔瑞菊 Traditional Chinese medicine preparation for treating diabetes
CN105663621A (en) * 2016-02-13 2016-06-15 成都富豪斯生物科技有限公司 Traditional Chinese medicine composition capable of effectively aiding diabetes treatment and preparing method thereof
CN109481571A (en) * 2018-12-19 2019-03-19 湖南希尔天然药业有限公司 A kind of mulberry leaf preparation and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127657A (en) * 1995-10-04 1996-07-31 张文龙 Tonic hypoglycemic capsule and preparing process thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127657A (en) * 1995-10-04 1996-07-31 张文龙 Tonic hypoglycemic capsule and preparing process thereof

Also Published As

Publication number Publication date
CN1175424A (en) 1998-03-11

Similar Documents

Publication Publication Date Title
CN101642529B (en) Preparation capable of treating diabetes
CN100493572C (en) Composition of medication for treating diabetes
CN1324627A (en) Diabetes treating medicine and its prepn. method
CN1052419C (en) Herb medicine for treating diabetes mellitus
CN102488830A (en) Pharmaceutical composition for lowering blood sugar
CN103055176B (en) Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof
CN102114185B (en) Medicament for treating insulin resistance of type 2 diabetes
CN1108159C (en) Traditional Chinese medicine for curing diabetes and kidney deficiency
CN103181945B (en) The purposes of Semen Luffae
CN105770087B (en) Mongolian medicinal composition for treating diabetes, hyperlipidemia and primary hyperviscosity
CN1911277A (en) Medicine for treating leukopenia
CN1272054C (en) Medicine for treating diabetes and its preparing process
CN1169547C (en) Medicine for treating diabetes and its preparation method
CN1205990C (en) Medicine for treating diabets mellitus
CN102430040A (en) Medicament for treating diabetes
CN1463734A (en) A prepared Chinese medicine for treating diabetes mellitus and method for preparing same
CN114191514B (en) Traditional Chinese medicine composition for preventing and treating phlegm-damp type obesity
CN1122524C (en) Chinese medicine for treating diabetes and its preparing process
CN1101213C (en) Diabetes treating medicine
CN100443092C (en) Granulocyte raised drug comprising cepharanthine
CN1306830A (en) Medicine for treating Type-11 diabetes
CN1211116C (en) Medicine for treating sympthetic nerve disorder
CN1111426C (en) Diabetes treating medicine
CN1589833A (en) Medicine for treating high blood pressure and its preparation method
CN1511554A (en) Medicinal composition for treating diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee